Bis(thiosemicarbazone) metal complexes as therapeutics for neurodegenerative diseases

S. McKenzie-Nickson, A. I. Bush, K. J. Barnham

Research output: Contribution to journalReview ArticleResearchpeer-review

19 Citations (Scopus)


Pathological aggregation of endogenous proteins is a common feature of many neurodegenerative diseases. This is generally accompanied by elevated levels of oxidative stress associated with transition metal dyshomeostasis. As such, strategies targeted toward rectifying metal imbalance are increasingly becoming an attractive therapeutic option. One class of compound showing such therapeutic potential are the bis(thiosemicarbazone) metal complexes. These are small, orally bioavailable compounds capable of crossing the blood brain barrier and capable of delivering bioavailable metal intracellularly. Members of this family of compounds have been shown to successfully treat animal models of several neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Here we review the current evidence for the efficacy of bis(thiosemicarbazone) metal complexes in treating these diseases and discuss the implications for future development of these compounds.

Original languageEnglish
Pages (from-to)3058-3068
Number of pages11
JournalCurrent Topics in Medicinal Chemistry
Issue number27
Publication statusPublished - 1 Nov 2016
Externally publishedYes


  • AD
  • ALS
  • Bis(thiosemicarbazone)
  • BTSC
  • Cu(atsm)
  • CU(gtsm)

Cite this